ALDVI: Advicenne S.A. - Summary | Jitta

Advicenne S.A.

FRA:ALDVI

Price
€1.27
Loss Chance
50.8%
3.52JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
186 / 502
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (49)
Recent Business Performance (62)
Financial Strength (33)
Return to Shareholders (16)
Competitive Advantage (54)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2024
Operating MarginDeclined
Recent Business PerformanceEarning decline 33.15% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.52
100.00%
4.50
90.73%
2.82
128.55%
Pharmaceuticals
3.28
100.00%
0.45
100.00%
4.96
66.02%
COMPANY DESCRIPTION
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.